40 studies found for:    " February 24, 2010":" March 26, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
21 Completed PENTA Fosamprenavir Study
Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: Exposure to licensed dose of FPV (+/- 20% of 18mg/kg BID + RTV)
22 Recruiting Antiretroviral Pregnancy Registry (APR)-Risk of Birth Defects
Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: Any Antiretroviral Therapy
23 Completed
Has Results
Evaluation of Kaletra Therapy Over the Long-term
Condition: Human Immunodeficiency Virus
Intervention: Drug: Lopinavir/Ritonavir (Kaletra)
24 Recruiting Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Condition: Human Immunodeficiency Virus
Intervention:
25 Completed
Has Results
Drug Use Investigation of Kaletra
Condition: Human Immunodeficiency Virus
Intervention: Drug: Lopinavir/ritonavir (Kaletra)
26 Recruiting Kaletra in Combination With Antiretroviral Agents
Condition: Human Immunodeficiency Virus
Intervention:
27 Completed
Has Results
Special Investigation of Kaletra in Pregnant Women
Condition: Human Immunodeficiency Virus
Intervention: Drug: Lopinavir/ritonavir (Kaletra)
28 Completed
Has Results
Long-term Effectiveness and Safety in Hepatitis-co-infected Patients
Condition: Human Immunodeficiency Virus-Infection
Intervention: Drug: Lopinavir/Ritonavir (Kaletra)
29 Completed Evaluation of the Public Health Interest of Kaletra: Impact on Resistance to Antiretrovirals (ARVs)
Condition: HIV Infection
Intervention:
30 Completed Cardiovascular Radiologic and Metabolic Assessment in HIV: An Investigation of Pathophysiology
Conditions: HIV;   Cardiovascular Disease
Intervention:
31 Completed A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients
Condition: HIV-1 Infection
Interventions: Drug: TBR-652;   Drug: TBR-652 Matching Placebo;   Drug: TBR-652 50 mg;   Drug: TBR-652 75 mg;   Drug: TBR-652 100 mg;   Drug: TBR-652 150 mg
32 Completed A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days
Condition: HIV-1 Infection
Intervention: Drug: Bevirimat
33 Enrolling by invitation " Arthrospira Platensis" as Nutrition Supplementation for Female Adult Patients Infected by HIV in Yaoundé Cameroon
Condition: HIV
Intervention: Dietary Supplement: Arthrospira platensis
34 Completed
Has Results
Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome
Condition: Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome
Intervention: Biological: Serostim
35 Completed GSK1349572 Drug Interaction Study With Efavirenz
Conditions: Infections, Human Immunodeficiency Virus and Herpesviridae;   Healthy
Interventions: Drug: GSK1349572;   Drug: Efavirenz
36 Unknown  A Computer-Based Parent/Adolescent HIV Communication Intervention for Latinos
Conditions: HIV/AIDS;   STD;   Pregnancy
Intervention: Behavioral: Computer-based parent-adolescent HIV communication
37 Completed Investigation of the Safety of an HIV-1 Vaccine Given Intra-muscularly and Intra-nasally to Healthy Female Subjects
Condition: HIV-1
Intervention: Biological: MYM-V101
38 Recruiting Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Conditions: Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   HIV-associated Hodgkin Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: lenalidomide;   Drug: temsirolimus;   Other: laboratory biomarker analysis
39 Recruiting Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
Conditions: Burkitt Lymphoma;   Diffuse Large B-cell Lymphoma, c-MYC Positive;   Plasmablastic Lymphoma
Interventions: Drug: EPOCH-R;   Drug: EPOCH-RR
40 Completed Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Condition: AIDS
Interventions: Procedure: Blood collection;   Biological: GSK HIV vaccine 732462

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page
Indicates status has not been verified in more than two years